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CCL25-mediated activation of CCR9 is critical for mucosal lymphocyte recruitment to the intestine. In
immune-mediated liver injury complicating inﬂammatory bowel disease, intrahepatic activation of this
pathway allows mucosal lymphocytes to be recruited to the liver, driving hepatobiliary destruction in
primary sclerosing cholangitis (PSC). However, in mice and healthy humans CCL25 expression is
restricted to the small bowel, whereas few data exist on activation of this pathway in the inﬂamed colon
despite the vast majority of PSC patients having ulcerative colitis. Herein, we show that colonic CCL25
expression is not only upregulated in patients with active colitis, but strongly correlates with endoscopic
Mayo score and mucosal TNFa expression. Moreover, approximately 90% (CD4þ) and 30% (CD8þ) of
tissue-inﬁltrating T-cells in colitis were identiﬁed as CCR9þ effector lymphocytes, compared to <10% of T-
cells being CCR9þ in normal colon. Sorted CCR9þ lymphocytes also demonstrated enhanced cellular
adhesion to stimulated hepatic sinusoidal endothelium compared with their CCR9e counterparts when
under ﬂow. Collectively, these results suggest that CCR9/CCL25 interactions are not only involved in
colitis pathogenesis but also correlate with colonic inﬂammatory burden; further supporting the exis-
tence of overlapping mucosal lymphocyte recruitment pathways between the inﬂamed colon and liver.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Immune cell entry into tissues is a highly coordinated process
controlled by the selective expression of cell adhesion receptors on
circulating leucocyte subsets and their respective ligands within
distinct vascular beds. In the gut, different intestinal sites show
distinct patterns of constitutive chemokine expression, which
compartmentalises different types of immune cells to particular
regions. For example, under non-inﬂammatory conditions the
chemokine CCL25 is expressed by small intestinal but not colonic
epithelium, where it supports the recruitment of T-cells and B-cells
expressing its receptor CCR9 [1]; whereas CCR10 and G Protein-th Research (NIHR) Birming-
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oi.org/10.1016/j.jaut.2016.01.0Coupled Receptor (GPR)-15 are involved in recruiting IgAþ plas-
mablasts and T-cells, respectively, to the colon [2e4]. These ﬁnd-
ings suggest that expression levels of chemokines may shape
regional differences in immune composition along the intestine.
However most of these studies have been done in mice [5,6], and
there is a relative paucity of information about the roles of CCL25
and CCR9 in the human colon under inﬂammatory conditions. This
is important as the CCR9/CCL25 pathway is being targeted to treat
inﬂammatory bowel disease (IBD) and evidence of upregulation in
active colitis would support clinical studies of anti-CCR9 therapy
[7]. To this effect, a recently published randomised controlled trial
in Crohn's disease demonstrated therapeutic beneﬁt of on oral
CCR9-antagonist over placebo only in the subset of patients with
colonic involvement [8].
The intestinal and hepatic immune systems are intimately
linked and venous drainage from the gut ﬂows through the liver.
The liver acts as a “ﬁrewall” and second site of immune regulationunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the gut [9]. This close relationship probably explains why the liver
is affected as an extra-intestinal site of injury in inﬂammatory
bowel disease (IBD) [10]; exempliﬁed by the fact that >80% of pa-
tients with the immune-mediated liver disease, primary sclerosing
cholangitis (PSC), develop colitis [11]. One hypothesis to explain the
clinical association between PSC and IBD suggests that mucosal
effector T-cells are recruited to the liver in response to aberrant
hepatic endothelial expression of adhesion molecules, which
ordinarily are restricted to the gut [12,13]. Although CCL25 is nor-
mally conﬁned to the small intestine, we have reported strong
expression on hepatic vessels in the inﬂamed liver, together with
that of another gut-associated adhesion molecule, mucosal
addressin cell-adhesion molecule (MAdCAM)-1 [12,13]; which
collectively drive recruitment of mucosal a4b7þCCR9þ effector T-
cells from gut to liver in PSC [12,13]. However, the IBD associated
with PSC is typically a colitis [14], and previous studies have failed
to detect tissue-inﬁltrating CCR9þ lymphocytes or mucosal CCL25
expression in the non-inﬂamed human colon [15e18].
In an effort to ‘‘bridge the link” across the aberrant mucosal
lymphocyte homing hypothesis [19], as well as our long-standing
interest in exploring shared lymphocyte trafﬁcking pathways that
exist between gut and liver, the aims of this study were to deter-
mine activity of the CCR9/CCL25 axis in the human colon under
inﬂammatory conditions.
2. Materials and methods
2.1. Intestinal tissue sampling
Intestinal tissue was obtained from patients undergoing surgery
for refractory UC or stricturing colonic Crohn's disease. Control
specimens were retrieved from ‘distal-to-tumour’ segments of
non-IBD associated colorectal cancer (NC) e an absence of colonic
inﬂammation being conﬁrmed histologically. Colonic mucosal bi-
opsies were obtained from patients with UC undergoing colono-
scopic surveillance as part of routine standard of care. Human liver
tissue was obtained through the Liver Unit at the Queen Elizabeth
Hospital, from explanted livers removed at transplantation. Ethical
approval was obtained from the local research and ethics com-
mittee and all patients granted full prior consent.
2.2. Preparation of tissue-inﬁltrating lymphocytes for ﬂow
cytometry
Mechanical digestion of tissue was carried out using the Gen-
tleMACS dissociator (Miltenyi Biotec Ltd, Surrey, UK) and mono-
nuclear cell extraction performed via gradient centrifugation, as
previously described [20]. The respective antibodies used to
phenotype subsets and appropriate isotype-matched controls are
provided in Supplementary Table 1. Samples were analysed in PBS/
1 mM EDTA/2% FBS using a CyAn ADP 3-laser, 9-colour ﬂow cy-
tometer (Beckman Coulter Inc, Brea, CA, USA). CCR9 positive pop-
ulations were deﬁned by gating on live, CD3þ, and either CD4þ or
CD8þ cells. Dead cells were excluded using Near-IR live/dead-
ﬁxable dye (Life Technologies Ltd, Paisley, UK).
2.3. Fluorescence-activated cell (FAC)-sorting and ﬂow-based
adhesion assays
To obtain puriﬁed populations of T-cells for functional assays,
antibody-labelled cells were sorted using a MoFlo XDP High-Speed
Cell Sorter (Beckman Coulter Inc., Brea, California, USA) in purity
mode.
Flow-based adhesion assays were conducted to compare thePlease cite this article in press as: P.J. Trivedi, et al., Intestinal CCL25 expre
Journal of Autoimmunity (2016), http://dx.doi.org/10.1016/j.jaut.2016.01.0ability of sorted a4b7þCCR9þ versus a4b7þCCR9e T-cells to adhere
and transmigrate across stimulated human hepatic sinusoidal
endothelial cells (HSEC) [21e23]. Brieﬂy, HSEC were extracted from
150 g explanted liver tissue as previously described [21e23] and
grown till conﬂuence. At passage 3e4, HSEC were transferred to
micro-capillaries for further culture, and when a conﬂuent mono-
layer was evident they were stimulated with TNFa and methyl-
amine as described by Liaskou et al. [22], prior to perfusion of
puriﬁed T-cell populations at a shear stress of 0.05 Pa. T-cells that
had adhered to HSEC were visualized by phase contrast microscopy
(10  objective) and classiﬁed as static (ﬁrmly adherent) or
migrated cells. Total adhesion was calculated as cells/mm2 nor-
malised to the number of lymphocytes perfused [23].
2.3.1. Protein immunoprecipitation and western blotting
Protein was extracted from 60 to 100 mg snap-frozen tissue by
incubation in ice-cold lysis buffer (CellLytic MT e SigmaeAldrich
Ltd, Dorset, UK) containing protease inhibitor (cOmplete Mini e
Roche, Indianapolis, USA), phosphatase inhibitor (phosSTOP e
Roche) and DNase I (Roche). Lysate protein concentrations were
determined against a protein standard using a bicinchoninic acid
(BCA) assay and normalised to 2 mg ml1.
Given that chemokines are often found at low levels in tissues
with a propensity to self-aggregate and multimerise [24], an
immunoprecipitation step (IP) was incorporated to enrich and
purify protein lysates. In brief, 0.6 mg of protein G Dynabeads® (Life
Technologies Ltd., Paisley, UK) were incubated with capture anti-
body (goat polyclonal anti-human CCL25; Cat No.: AF334 e R&D
systems, Minneapolis, USA) at ambient temperature under
continuous rotation (1 h) and the sample lysate added (continuous
rotation; 1 h). Magnetic separation was used to obtain bead bound
protein, and non-bound cleared lysate kept for analysis of house-
keeping protein and as a negative internal control for the primary
target. The remaining bead-bound sample was washed and sub-
jected to temperature dissociation (70 C, 20 min) to remove beads
prior to resuspension in SDS-PAGE sample buffer (200 mM Trizma
Base pH 6.8, 20% glycerol, 10% SDS, 0.05% bromophenol blue,10mM
b-mercaptoethanol).
Immunoprecipitated protein or cleared lysate (20 mg) from each
sample was resolved on a 12% SDSePAGE gel and transferred to a
nitrocellulose membrane. Membranes were blocked in 5% non-fat
milk dissolved in PBS-Tween20 at ambient temperature (1 h) and
subsequently incubated overnight at 4C with primary detection
antibody (mouse raised against human CCL25: Clone 52529 e R&D
systems; or clone 1.2_4G1-1G4-1C9 e Peprotech, New Jersey, USA)
or housekeeping protein (mouse raised against human b-actin:
clone AC-74 e Sigma) diluted in 5% milk/PBS-Tween20. The
following day, membranes were incubated with horseradish
peroxidase conjugated anti-mouse secondary antibodies (1 h;
ambient temperature) (Dako Ltd., Cambridge, UK; 1/2500 dilution).
Protein bands were detected with the PicoWest ECL system
(Thermo Fisher Scientiﬁc Inc., Rockford, USA). Membranes were not
stripped.
2.3.2. Enzyme-linked immunosorbent assay (ELISA)
ELISA for detection of CCL25 was performed on protein lysates
from resected tissue according to manufacturers instructions
(2bScientiﬁc Ltd., Upper Heyford, UK).
2.4. Gene-expression studies
RNA was extracted from snap-frozen tissue samples using the
Qiagen RNeasy mini-kit with on column DNase digestion (Qiagen
GmBH, Hilden, Germany). Quantiﬁcation and purity of RNA was
determined by UV absorbance at 260 nm and 280 nm (Implenssion is increased in colitis and correlates with inﬂammatory activity,
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adjusted to 50 mg ml1. One microgram of RNA was reverse-
transcribed using the iScript cDNA synthesis kit (Bio-Rad Inc, Her-
cules, USA). Differences in targetmRNA expression between UC and
NC was determined in triplicate for each sample by quantitative
real-time PCR (qRT-PCR) (Roche Lightcycler 480; TaqMan Assay
Mix, Life Technologies). All primers and probes spanned exoneexon
junctions and were pre-designed and obtained from Life Technol-
ogies (Supplementary Table 2). For relative quantiﬁcation analysis,
data were normalised to the appropriate housekeeping gene using
‘E-analysis’ (Roche) and the device software (version 1.5.0.39). We
have recently determined GUS-b as being highly conserved by
GeNORM and Bestkeeper algorithms in normal colon as well as
colonic cancer [20]. Indeed, GUS-b illustrated stable expression
between UC and NC specimens, as well as across ordinal degrees of
colonic inﬂammatory activity (data not shown), and was therefore
considered a suitable housekeeping gene for assessment in this
context.2.5. Statistical analysis
The distribution of continuous variables was tested using the
KolmogoroveSmirnov test. Non-parametric data are presented as
median and interquartile range (IQR); or mean and standard de-
viation (SD) if conﬁrming to a normal distribution. The Man-
neWhitney (MW) test and the Kruskal-Wallis test were conducted
when comparing between two or more independent groups,
respectively. Non-parametric measures of statistical dependence
between two continuous variables were conducted using Spear-
man's rank correlation coefﬁcient.3. Results
3.1. CCR9þ T-cells are present in inﬂamed but not normal human
colon
Consistent with prior reports, we found that 62.4% (SD ±19.7%)
of tissue-inﬁltrating CD4þ and 68.2% (±12.4%) of CD8þ T-cells were
CCR9 positive in the terminal ileum/small bowel (Fig. 1A) whereas
very few CCR9þ T-cells were detected in normal colon (5.5 ± 0.5%
and 4.9 ± 2.4%, respectively). In contrast, specimens from patients
with ulcerative colitis refractory to medical therapy contained
signiﬁcantly more CCR9 expressing CD4þ (92.6 ± 4.1%; p < 0.001)
and CD8þ T-cells (34.3 ± 3.8%; p ¼ 0.013) than non-inﬂamed colon.
Increased frequencies albeit at lower levels were also seen in large
bowel specimens with only microscopic colitis. The majority of
CD4þ CCR9þ T-cells were CD127þ, with little or no expression of
CD25. Collectively, these ﬁndings suggest that effector CCR9þ
lymphocytes, but not regulatory T-cells (Treg), inﬁltrate the
inﬂamed colon (Fig. 1B).
Phenotypically, UC is characterised by continuous involvement
of the colon starting at the rectum and showing variable proximal
extension [25]. Crohn's disease on the other hand is typiﬁed by the
presence of skip lesions in which regions of active disease are
interspersed with segments free of inﬂammatory involvement [26].
To test the hypothesis that colonic CCR9þ lymphocytes are
restricted to areas of active inﬂammation, we compared tissue-
inﬁltrating T-cell populations in resected Crohn's inﬂammatory
strictures with those in neighbouring segments of uninvolved co-
lon (Fig. 1C). In the cases studied, >80% of CD4þ and >40% of CD8þ
T-cells in regions of active inﬂammatory stricturing were CCR9
positive compared with ~30% and ~7% in non-inﬂamed colon from
the same patients.Please cite this article in press as: P.J. Trivedi, et al., Intestinal CCL25 expre
Journal of Autoimmunity (2016), http://dx.doi.org/10.1016/j.jaut.2016.01.03.2. a4b7þCCR9þ T-cells undergo adhesion and transmigration
across HSEC
We have previously shown that HSEC can support the recruit-
ment of gut-tropic a4b7þ lymphocytes, following endothelial
stimulation with TNFa and methylamine [22]. Extending these
observations further, a signiﬁcantly greater proportion of FAC-
sorted a4b7þCCR9þ T-cells underwent adhesion to stimulated
HSEC under ﬂow, relative to that observed for a4b7þCCR9e T-cells
(Supplementary Fig. 1).
3.3. Colonic CCL25 expression is upregulated in colitis
Having demonstrated a population of tissue-inﬁltrating CCR9þ
T-cells in the inﬂamed colon, we proceeded to look for its cognate
ligand. Indeed, CCL25 mRNA expression was detected in resected
colonic tissue from patients with refractory colitis (n ¼ 10; median
expression relative to GUS-b: 9.6ε 4; IQR 2.0ε 4 e 3.2ε 3) but not
in normal colonic tissue (n ¼ 10). These differences were reﬂected
in increased CCL25 protein expression measured by immunopre-
cipitation andwestern blotting (Fig. 2A), and conﬁrmed using ELISA
analysis of the same tissue protein lysates (Fig. 2B).
3.4. CCL25 expression in the colon correlates with severity of colitis
To determine whether CCL25 expression is detectable in colitis
during earlier stages of inﬂammation, mucosal biopsies were ob-
tained from individuals with ulcerative colitis undergoing colo-
noscopy as part of routine standard of care (kindly provided by
University Hospital Jena (Germany); Table 1). Although mucosal
biopsies are not large enough for protein or single cell ﬂow-
cytometry analysis, we were able to quantify CCL25 mRNA
expression and demonstrate a signiﬁcant correlation with both
mucosal inﬂammation as assessed by the endoscopic Mayo score,
and colonic TNFa transcription as an alternative marker of in-
ﬂammatory activity (Fig. 2C and D).
No signiﬁcant differences in CCL25 expression were revealed
between colonic biopsy site, treatment status with amino-
salicylates, immunosuppressive exposure (stratiﬁed according to
use of steroids, thiopurines, calcineurin inhibitors, biological ther-
apy) or patient age (data not shown).
4. Discussion
Evidence form murine studies suggest that CCL25 and CCR9 are
involved in lymphocyte recruitment to the small intestine but not
the colon. We now show that although CCL25 is largely absent from
non-inﬂamed human colon, expression is markedly upregulated in
colitis and correlates with inﬂammatory activity. Moreover, CCL25
expression in the colon is associated with high frequencies of
CCR9þ tissue-inﬁltrating effector T-cells in patients with colitis,
which exhibit increased potential toward adhesion to liver endo-
thelium. These ﬁndings are important for several reasons: ﬁrstly
they support a role for CCL25 expression and CCR9þ effector cells in
colitis and show that CCR9-dependent recruitment is not conﬁned
to regulatory cells; secondly they suggest that CCR9 is a potential
therapeutic target in UC as well as colonic Crohn's disease [8,27],
and thirdly they support a pathogenic role for effector T-cells
activated in the colon, which have also been identiﬁed as being pro-
inﬂammatory in PSC liver [12].
CCR9 is expressed on nearly all intraepithelial lymphocytes
(IELs) and lamina propria lymphocytes (LPLs) in the jejunum, and at
high frequencies in the terminal ileum [15]. In contrast, relatively
few T-cells are reportedly CCR9 positive in the colon or mesenteric
lymph nodes (MLN) [18]. Moreover, Papadakis et al. found lowssion is increased in colitis and correlates with inﬂammatory activity,
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Fig. 1. CCR9 Expression of Tissue-Inﬁltrating T-Cells in Small and Large Bowel. Representative ﬂow cytometry plots illustrating [A] percentage CCR9 expression on intestinal CD4þ
and CD8þ T-cells in terminal ileum/small bowel (SB; n ¼ 5), non-inﬂamed colon (NC; n ¼ 5), ulcerative colitis (UC; n ¼ 6) and UC resection specimens without evidence of
macroscopic inﬂammation (UC (m); n ¼ 4). Fluorescence minus one (FMO) controls were used to determine speciﬁcity of staining for CCR9: red histograms indicate positive
antibody staining and grey, the isotype-matched control. CD4þ CCR9þ T-cells inﬁltrating the inﬂamed colon expressed high levels of CD127 but little CD25 [B]. The proportions of
CD4þ and CD8þ CCR9þ T-cells were also determined in Crohn's resection specimens [C] (n ¼ 2); wherein, red histograms indicate active inﬂammatory stricturing, blue histograms
represent adjacent areas of non-active disease, and grey the isotype-matched controls (from areas of active stricturing). All plots are gated on live, CD3þ cells.
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tients with colonic as opposed to small bowel Crohn's disease [28].
The same group reported low frequencies of CD3þCCR9þ cells in
normal human colonic mucosa, consistent with our ﬁndings [18].
However, none of these studies looked in detail at inﬂamed human
colon. We not only detected elevated frequencies of CCR9þ T-cells
in active macroscopic colitis but also saw high (albeit relatively
fewer) numbers in microscopic colitis. Taken together, our ﬁndings
imply that activation of this pathway takes place early in colitis and
is upregulated with disease activity [29].
Ccl25 gene expression is restricted to the small intestine in
uninjured wild type mice [16,30,31] as well as the Samp1/YitFc
model of IBD [32]. Similar results are reported in the TnfDARE model
of small bowel Crohn's disease [33], Rag2/ mice [34] and studies
in higher order mammals [35]. Nevertheless, certain studies do
report colonic Ccl25 transcripts in spontaneous murine models of
colitis [36], as well as colonic inﬂammation induced by dextran
sulphate sodium [37,38] and oxazolone [39]. We extend upon these
observations by showing a striking positive correlation between
human colonic CCL25 gene expression and inﬂammatory indices
across two patient cohorts with ulcerative colitis, in association
with detectable CCL25 protein levels and a CCR9þ colon-inﬁltrating
effector T-cell population. These ﬁndings may also contribute to thePlease cite this article in press as: P.J. Trivedi, et al., Intestinal CCL25 expre
Journal of Autoimmunity (2016), http://dx.doi.org/10.1016/j.jaut.2016.01.0colonic cancer risk in IBD which relates to inﬂammatory burden,
given the ability of CCR9/CCL25 interactions to mediate colonic
tumour growth, invasion and metastasis [40].
The potential to imprint gut-tropism onto lymphocytes was
long-believed as restricted to intestinal dendritic cells (DC) within
the lamina propria andMLN [41], although works from the Blizzard
institute (London, UK) have recently identiﬁed DC and CD14þ
macrophages from the inﬂamed human colon as also possessing
such capabilities [42]. Moreover, murine studies suggest that HSEC
under certain circumstances can imprint gut-tropism through the
generation of a4b7þCCR9e T-cells. However, under such circum-
stances ‘HSEC-primed’ T-cells are dominated by regulatory func-
tions, rather than ‘gut-primed’ a4b7þCCR9þ T-cells which exhibit
an effector phenotype [43e45]. Our data builds upon these ﬁndings
by showing how a4b7þCCR9þ T-cells undergo enhanced adhesion
and transmigration across stimulated liver endothelium compared
with their a4b7þCCR9e counterparts. In view of the evolving use of
anti-CCR9 therapies in IBD, these ﬁndings support therapeutic
exploration in models exhibiting concomitant features of chol-
angitis and colitis [45,46]; of particular relevance given that it is the
CCR9 positive subset of mucosal T-cells which are implicated in the
pathogenesis of PSC [12].
If CCL25 expression is driven by colitis activity, and colonicssion is increased in colitis and correlates with inﬂammatory activity,
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Fig. 2. Colonic CCL25 Expression under Non- and Pro-Inﬂammatory Conditions. CCL25 protein expression was determined by western blots post-immunoprecipitation, I.P. [A],
probing for CCL25 in tissue lysates of resected terminal ileum/small bowel (SB), large bowel afﬂicted with ulcerative colitis (UC) and non-inﬂamed colon (NC). Band sizes in keeping
with dimeric CCL25 are illustrated for samples probed following I.P. (þ), the paired cleared lysate (), and b-actin (housekeeping; cleared lysates only). Membranes bearing NC
samples were subject to greater exposure times given the relatively low abundance/absence of CCL25 under non-inﬂammatory conditions and are therefore shown as a separate
group. Differential expression of CCL25 in tissue samples was conﬁrmed by ELISA [B]. Correlation with inﬂammatory burden was assessed in mucosal biopsy samples obtained
during routine, surveillance colonoscopy (n ¼ 37) by qRT-PCR. Given that CCL25 gene expression was not detectable in non-inﬂamed colon (control), data are presented relative to
GUS-b (housekeeping gene) across endoscopic Mayo severity scores [C] and in correlation with TNFa expression [D]. Asterisks are indicative of statistically signiﬁcant differences.
Table 1
Characteristics of patients undergoing colonoscopic surveillance (n ¼ 37).
Patient characteristic Number of patients (%)
Median age (IQR) 38yrs. (26e46)
Male; N (%) 22 (59)
Biopsy site; N (%)
- rectum 13 (35)
- sigmoid 16 (43)
- descending colon 3 (8)
- transverse colon 1 (3)
- ascending colon 2 (5)
- caecum 2 (5)
Endoscopic Mayo score; N (%)
0 11 (30)
1 11 (30)
2 10 (27)
3 5 (14)
Primary sclerosing cholangitis; N (%) 3 (8)
Aminosalicylates
- Oral 29 (78)
- Topical 2 (5)
Immunosuppression; N (%)a
- Any 21 (57)
- Corticosteroid (oral)b 9
- Corticosteroid (topical)c 3
- Anti-proliferatived 8
- Biologice 10
- Calcineurin inhibitor 1
a Includes those on combination therapy with >1 agent.
b Prednisolone was utilised in all cases.
c Budesonide or hydrocortisone.
d Azathioprine, 6-Mercaptopurine of Methotrexate.
e Inﬂiximab or Adalimumab.
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tion in PSC, then it should follow that the risk of PSC increases with
intestinal activity; an observation which does not hold true clini-
cally. However, pre-exposure of primed CCR9þ T-cells to high CCL25
levels in the gut during the onset of active IBD, may be capable of
modulating subsequent migratory responses [47]. In such a model,
pro-inﬂammatory, effector mucosal CCR9þ T-cells would be pref-
erentially recruited to the gut during the onset of active colonic
disease in response to high levels of intestinal CCL25 expression.
Thereafter, mucosal T-cells would down-regulate expression of
active CCR9 (“chemokine desensitisation”), favouring local reten-
tion in the gut for as long as colonic inﬂammation persists. On
achieving remission from a colitis ﬂare, the colonic CCL25 gradient
is attenuated, and primed mucosal CCR9þ lymphocytes now
become permissive to recruitment to the liver sinusoids in response
to aberrant hepatic endothelial CCL25 expression e as observed in
the PSC liver [12]. Of interest, the risk of PSC disease recurrence
following liver transplantation appears greatest in patients with
IBD who retain an intact colon [48e50]. However, the precise fac-
tors regulating endothelial expression of CCL25 in the native (and
indeed transplanted) liver remain elusive, and command further
investigation.
In summary, we report the involvement of CCL25 and CCR9
effector T-cells in colonic inﬂammation, providing further evidence
to support a role for CCR9 in lymphocyte homing to the large bowel.
Given the strong links between hepatobiliary inﬂammation and the
presence of IBD, these ﬁndings when taken together with ourssion is increased in colitis and correlates with inﬂammatory activity,
01
P.J. Trivedi et al. / Journal of Autoimmunity xxx (2016) 1e76previously published data, support a role of CCR9/CCL25 in-
teractions in driving recruitment of mucosal effector cells to the gut
as well as liver in patients with ulcerative colitis.
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